Bladder cancer study aims to uncover hidden energy costs of treatment
NCT ID NCT06721260
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks how bladder cancer treatment affects patients' energy needs and muscle function. Researchers will measure resting energy use and collect blood samples from 30 patients before and after chemotherapy and surgery. The goal is to learn more about these changes so future care can be better tailored to patients' needs.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better understand and address energy and muscle changes in bladder cancer patients, leading to improved supportive care during treatment.
- What could go wrong
- This is a small, early observational study (30 people) that measures changes but does not test a new treatment. Results may not apply to all patients or lead to direct changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Potential patients will be scheduled for treatment (chemotherapy and radical cystectomy) for bladder cancer at the University of Kansas Health System.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Confirmed cancer diagnosis * Scheduled for platinum-based chemotherapy followed by radical cystectomy * Adequate renal and cardiac function for platinum-based chemotherapy Exclusion Criteria: * Prior chemotherapy or radiotherapy for bladder cancer * Severe cardiac, renal, hepatic, respiratory or metabolic diseases * Pregnant or breastfeeding * Uncontrolled conditions that could affect study outcomes
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bladder cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Kansas Medical Center
RECRUITINGKansas City, Kansas, 66160, United States
-
University of Kansas Medical Center
RECRUITINGKansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lab-Grown tumor organoids could pick the right bladder chemo
- Can tumor genes decide who keeps their bladder?
- Lab-Grown tumor models could match patients to the right cancer drug
- Can heated saline during bladder surgery stop tumors from coming back?
- Can a radioactive antibody light up hidden tumors on PET scans?
- Can a radioactive drug seek out and attack solid tumors?